{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:08:24Z","timestamp":1776247704834,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10549-026-07909-5","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T04:38:45Z","timestamp":1770266325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudy"],"prefix":"10.1007","volume":"215","clinical-trial-number":[{"clinical-trial-number":"nct00279448","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00032136","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00036270","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Andr\u00e9anne","family":"Leblanc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana-Alicia","family":"Beltran-Bless","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory R.","family":"Pond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"El Emam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamin","family":"Juwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Bayani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Pilgram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Pharoah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Mallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Markopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Dirix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Vandermeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie France","family":"Savard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M. S.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"7909_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07596-0","author":"K Cooper","year":"2025","unstructured":"Cooper K et al (2025) Gene expression profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review. Breast Cancer Res Treat. https:\/\/doi.org\/10.1007\/s10549-024-07596-0","journal-title":"Breast Cancer Res Treat"},{"issue":"10502","key":"7909_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0140-6736(25)00832-3","volume":"406","author":"E Brain","year":"2025","unstructured":"Brain E et al (2025) Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial. Lancet 406(10502):489\u2013500","journal-title":"Lancet"},{"issue":"3","key":"7909_CR3","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/curroncol31030096","volume":"31","author":"AA Awan","year":"2024","unstructured":"Awan AA et al (2024) Does pre-emptive availability of PREDICT 2.1 results change ordering practices for Oncotype DX? A multi-center prospective cohort study. Curr Oncol 31(3):1278\u20131290","journal-title":"Curr Oncol"},{"key":"7909_CR4","volume":"5","author":"A Batra","year":"2019","unstructured":"Batra A et al (2019) Oncotype DX: where does it stand in India? J Glob Oncol 5:JGO. 19.00151","journal-title":"J Glob Oncol"},{"issue":"3","key":"7909_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.molonc.2007.10.004","volume":"1","author":"F Cardoso","year":"2007","unstructured":"Cardoso F, Piccart-Gebhart M, Van\u2019t Veer L, Rutgers E (2007) The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol Oncol 1(3):246\u2013251","journal-title":"Mol Oncol"},{"key":"7909_CR6","unstructured":"National Institute For Health And Care Excellence. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. May 2024 June 10 2025]; Available from: https:\/\/www.nice.org.uk\/guidance\/dg58."},{"issue":"1","key":"7909_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12962-023-00449-5","volume":"21","author":"L Rojas","year":"2023","unstructured":"Rojas L et al (2023) Cost-utility analysis of genomic profiling in early breast cancer in Colombia. Cost Eff Resour Alloc 21(1):42","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"7909_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.6004\/jnccn.2018.7077","volume":"17","author":"S-Y Wang","year":"2019","unstructured":"Wang S-Y et al (2019) Incorporating tumor characteristics to maximize 21-gene assay utility: a cost-effectiveness analysis. J Natl Compr Canc Netw 17(1):39\u201346","journal-title":"J Natl Compr Canc Netw"},{"key":"7909_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104528","author":"A-A Beltran-Bless","year":"2025","unstructured":"Beltran-Bless A-A et al (2025) Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)? Breast. https:\/\/doi.org\/10.1016\/j.breast.2025.104528","journal-title":"Breast"},{"issue":"13","key":"7909_CR10","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1002\/cam4.3088","volume":"9","author":"DA Goldstein","year":"2020","unstructured":"Goldstein DA et al (2020) The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer. Cancer Med 9(13):4603\u20134612","journal-title":"Cancer Med"},{"issue":"2","key":"7909_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.hemonc.2019.02.001","volume":"12","author":"S Thibodeau","year":"2019","unstructured":"Thibodeau S, Voutsadakis IA (2019) Prediction of Oncotype Dx recurrence score using clinical parameters: a comparison of available tools and a simple predictor based on grade and progesterone receptor. Hematol Oncol Stem Cell Ther 12(2):89\u201396","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"1","key":"7909_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-016-4093-4","volume":"162","author":"MR Harowicz","year":"2017","unstructured":"Harowicz MR et al (2017) Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. Breast Cancer Res Treat 162(1):1\u201310","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7909_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10549-025-07654-1","volume":"211","author":"RB Basmadjian","year":"2025","unstructured":"Basmadjian RB et al (2025) Evaluating PREDICT and developing outcome prediction models in early-onset breast cancer using data from Alberta, Canada. Breast Cancer Res Treat 211(2):399\u2013408","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"7909_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-023-01612-9","volume":"25","author":"A Chowdhury","year":"2023","unstructured":"Chowdhury A, Pharoah PD, Rueda OM (2023) Evaluation and comparison of different breast cancer prognosis scores based on gene expression data. Breast Cancer Res 25(1):17","journal-title":"Breast Cancer Res"},{"issue":"6","key":"7909_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.20.03007","volume":"39","author":"JA Sparano","year":"2021","unstructured":"Sparano JA et al (2021) Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer. J Clin Oncol 39(6):557\u2013564","journal-title":"J Clin Oncol"},{"issue":"1","key":"7909_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0852-3","volume":"19","author":"FJ dos Candido Reis","year":"2017","unstructured":"dos Candido Reis FJ et al (2017) An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Res 19(1):58","journal-title":"Breast Cancer Res"},{"issue":"1","key":"7909_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41523-024-00612-y","volume":"10","author":"I Grootes","year":"2024","unstructured":"Grootes I, Wishart GC, Pharoah PDP (2024) An updated PREDICT breast cancer prognostic model including the benefits and harms of radiotherapy. NPJ Breast Cancer 10(1):6","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"7909_CR18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.eururo.2011.04.029","volume":"60","author":"CT Nguyen","year":"2011","unstructured":"Nguyen CT, Kattan MW (2011) How to tell if a new marker improves prediction. Eur Urol 60(2):226\u20138","journal-title":"Eur Urol"},{"issue":"2","key":"7909_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/tbj.13197","volume":"25","author":"G Mariani","year":"2019","unstructured":"Mariani G et al (2019) Single institution trial of anthracycline\u2010and taxane\u2010based chemotherapy for operable breast cancer: the ASTER study. Breast J 25(2):237\u2013242","journal-title":"Breast J"},{"key":"7909_CR20","unstructured":"Boyer, M.J., et al., (2023) Prognostic Value of Genomic Classifier Testing for Prostate Cancer: A Systematic Review."},{"issue":"2","key":"7909_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/bimj.201000078","volume":"53","author":"NR Cook","year":"2011","unstructured":"Cook NR, Paynter NP (2011) Performance of reclassification statistics in comparing risk prediction models. Biom J 53(2):237\u2013258","journal-title":"Biom J"},{"issue":"1","key":"7909_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41523-021-00297-7","volume":"7","author":"JMS Bartlett","year":"2021","unstructured":"Bartlett JMS et al (2021) Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study. NPJ Breast Cancer 7(1):90","journal-title":"NPJ Breast Cancer"},{"issue":"9762","key":"7909_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","volume":"377","author":"CJ van de Velde","year":"2011","unstructured":"van de Velde CJ et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377(9762):321\u2013331","journal-title":"Lancet"},{"issue":"9","key":"7909_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238593","volume":"15","author":"JMS Bartlett","year":"2020","unstructured":"Bartlett JMS et al (2020) Computational approaches to support comparative analysis of multiparametric tests: modelling versus training. PLoS ONE 15(9):e0238593","journal-title":"PLoS ONE"},{"issue":"2","key":"7909_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA et al (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111\u2013121","journal-title":"N Engl J Med"},{"issue":"5","key":"7909_CR26","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.ejso.2011.03.082","volume":"37","author":"S-W Loh","year":"2011","unstructured":"Loh S-W, Rodriguez-Miguelez M, Pharoah P, Wishart G (2011) A comparison of chemotherapy recommendations using Predict and Adjuvant models. Eur J Surg Oncol 37(5):S21\u2013S22","journal-title":"Eur J Surg Oncol"},{"key":"7909_CR27","doi-asserted-by":"publisher","DOI":"10.1159\/000546080","author":"N Ditsch","year":"2025","unstructured":"Ditsch N, Gnant M, Thomssen C, Harbeck N (2025) St. Gallen\/vienna summary of key messages on therapy in early breast cancer from the 2025 St. Gallen international breast cancer conference (SGBCC). Breast Care. https:\/\/doi.org\/10.1159\/000546080","journal-title":"Breast Care"},{"issue":"1","key":"7909_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41523-017-0034-6","volume":"3","author":"SM Stemmer","year":"2017","unstructured":"Stemmer SM et al (2017) Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry. NPJ breast cancer 3(1):33","journal-title":"NPJ breast cancer"},{"issue":"5","key":"7909_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1778","volume":"9","author":"JA van der Hage","year":"2007","unstructured":"van der Hage JA et al (2007) Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis. Breast Cancer Res 9(5):R70","journal-title":"Breast Cancer Res"},{"key":"7909_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10549-020-05931-9","volume":"185","author":"K Losk","year":"2021","unstructured":"Losk K et al (2021) Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Res Treat 185:215\u2013227","journal-title":"Breast Cancer Res Treat"},{"key":"7909_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-021-01453-4","volume":"23","author":"E Schaafsma","year":"2021","unstructured":"Schaafsma E et al (2021) Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use. Breast Cancer Res 23:1\u201311","journal-title":"Breast Cancer Res"},{"key":"7909_CR32","unstructured":"National Comprehensive Cancer Network. 2025 Clinical Practice Guideline in Oncology: Breast Cancer. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"issue":"4","key":"7909_CR33","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2001.19.4.980","volume":"19","author":"PM Ravdin","year":"2001","unstructured":"Ravdin PM et al (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19(4):980\u2013991","journal-title":"J Clin Oncol"},{"issue":"8","key":"7909_CR34","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso F et al (2016) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375(8):717\u2013729","journal-title":"N Engl J Med"},{"key":"7909_CR35","volume-title":"TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score","author":"JA Sparano","year":"2018","unstructured":"Sparano JA et al (2018) TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score. American Society of Clinical Oncology, Alexandria"},{"issue":"25","key":"7909_CR36","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K et al (2021) 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med 385(25):2336\u20132347","journal-title":"N Engl J Med"},{"issue":"8","key":"7909_CR37","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F et al (2019) Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(8):1194\u20131220","journal-title":"Ann Oncol"},{"issue":"16","key":"7909_CR38","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1200\/JCO.22.00069","volume":"40","author":"F Andre","year":"2022","unstructured":"Andre F et al (2022) Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol 40(16):1816\u20131837","journal-title":"J Clin Oncol"},{"issue":"18","key":"7909_CR39","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","volume":"247","author":"FE Harrell","year":"1982","unstructured":"Harrell FE et al (1982) Evaluating the yield of medical tests. JAMA 247(18):2543\u20132546","journal-title":"JAMA"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07909-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07909-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07909-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T09:29:04Z","timestamp":1770802144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07909-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7909"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07909-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.L has no relevant financial or non-financial interests to disclose. A-A.B-B has no relevant financial or non-financial interests to disclose. G.R.P. has received consultancy from Takeda, Merck, Profound Medical and honoraria from AstraZeneca. Also has a close family member who is employed by Roche Canada and who owns stock in Roche Ltd. J.B has received honoraria from Thermo Fisher Scientific, Nanostring Technologies and research funding from Thermo Fisher Scientific.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ottawa Hospital Science Network Research Ethics Board (OHSN-REB 20210493-01H) and the University of Toronto (REB# 35339).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"74"}}